Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced ...

Samsung Biologics reported consolidated revenue of KRW 1.3 trillion in the first quarter of 2025, mainly driven by the stable ramp-up of Plant 4 while maintaining the full utilization of Plants 1 ...

Samsung Biologics celebrated the 14th anniversary of its founding on Monday, marking its rise to become the world’s largest contract development and manufacturing organization (CDMO).

FIRST QUARTER 2025 RESULTS Samsung Biologics reported consolidated revenue of KRW 1.3 trillion in the first quarter of 2025, mainly driven by the stable ramp-up of Plant 4 while maintaining the ...

Samsung Biologics' first-quarter revenue grew 37% to KRW 1.3 trillion, driven by higher contribution from the completion of Plant 4 in 2024, strong biosimilar sales, and favorable currency impact.

"We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our clients," said John Rim, CEO and President of Samsung ...

Samsung Biologics announced on April 28 that it had signed a 737.3 billion won ($5.4 billion) contract to manufacture ...